ArticleScience (New York, N.Y.)2013
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
Article in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02666755 (Novel Detection System for Detecting Epidermal Growth Factor Receptor Mutation in Plasma in Non-small Cell Lung Cancer), which is not on this map. Cited by 1,435 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Novel Detection System for Detecting Epidermal Growth Factor Receptor Mutation in Plasma in Non-small Cell Lung Cancer
Who cites it
1,435 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,437 citations in OpenAlex.
- Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials.Molecular oncology · 2025Trial
- CT-based Intratumoral Heterogeneity Score for Preoperative Prediction of Lymphovascular Invasion and Prognosis in Lung Adenocarcinoma: A Multicenter Validation and Radiogenomic Interpretation.Annals of surgical oncology · 2026Article
- Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells.Exploration (Beijing, China) · 2026Review
- NNMT-associated metabolic-thromboinflammatory-immune co-activation in heterogeneous CTC clusters: a hypothesis-generating computational framework".BMC cancer · 2026Article
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients.The journal of liquid biopsy · 2026Article
- MUC1 as a Survival Effector of Radiotherapy-Induced Epithelial Hybrid States in Basal-Like Breast Cancer.International journal of cancer · 2026Article
- Epithelial-mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis.Cancer metastasis reviews · 2026Review
- Adaptive epithelial-mesenchymal bi-directional transition: A key invasive plasticity for tumor metastasis.iScience · 2026Review
- Attention U-Net-Based Segmentation and Hybrid Classification for Detection of Circulating Tumor-Associated Cells.Cancers · 2026Article
- Integrated Molecular and Phenotypic Profiling of Circulating Tumor Cells in Gastric Cancer: A Translational Perspective.FASEB bioAdvances · 2026Article
- Spatiotemporal heterogeneity in non-small cell lung cancer: A paradigm shift from characterization to dynamic management (Review).Oncology letters · 2026Review
- Review
- Single-cell RNA sequencing of circulating tumour cells in colorectal cancer.Molecular biology reports · 2026Article
- TIA1 depletion enhances CLSTN1 exon 11 inclusion to facilitate Epithelial-to-Mesenchymal transition and breast cancer metastasis.Oncogene · 2026Article
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASHuman cell · 2026Article
- Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.NPJ breast cancer · 2026Review
- Radiotherapy, EMP and dormancy in TME: An integrated perspective on tumor microenvironments and long-term relapse.iScience · 2026Review
- Review
1,375 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
Abstract
Epithelial-mesenchymal transition (EMT) of adherent epithelial cells to a migratory mesenchymal state has been implicated in tumor metastasis in preclinical models. To investigate its role in human cancer, we characterized EMT in circulating tumor cells (CTCs) from breast cancer patients. Rare primary tumor cells simultaneously expressed mesenchymal and epithelial markers, but mesenchymal cells were highly enriched in CTCs. Serial CTC monitoring in 11 patients suggested an association of mesenchymal CTCs with disease progression. In an index patient, reversible shifts between these cell fates accompanied each cycle of response to therapy and disease progression. Mesenchymal CTCs occurred as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)-β pathway components and the FOXC1 transcription factor. These data support a role for EMT in the blood-borne dissemination of human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.